Prevalence of reactogenicity of COVID-19 vaccine among Libyan adults: a cross-sectional study

Abstract :

The diversity of reactogenicity and its variation in terms of risk and prevalence among populations has raised the need to study and evaluate the reactogenicity of different COVID-19 vaccines in our region. Thus, this study aimed to estimate the prevalence of reactogenicity of COVID-19 vaccines and compare the three vaccines (AstraZeneca-Oxford, Sinovac and Sputnik V). An analytical cross-sectional study was conducted using a semi-structured telephonic interview with a sample size of 430 individuals who received one of the included COVID-19 vaccines (AstraZeneca, Sinovac or Sputnik V) and were recorded at one of the vaccination centers' records that were affiliated with Aljamail Department of the National Centre for Disease Control, Libya. 410 Libyan participants met the inclusion criteria and were enrolled in the final analysis. The study has shown that 57.3% (CI 52.7-62) of the participants had at least one reactogenic event. Pyrexia (40.7%), headache (27.3%) and fatigue (19.5%) were the most common reactogenic events. In conclusion: the study found that reactogenic events were mild to moderate and the COVID-19 vaccines were safe and encouraged our community to be vaccinated. However, prospective studies with larger sample sizes, longer follow-up and inclusion of important laboratory parameters such as IgG and IgM immunoglobulins are recommended to better understand the relationship between the reactogenicities of COVID-19 vaccines with immunity system development and the factors associated with it.

References

1. Li Y Der, Chi WY, Su JH, Ferrall L, Hung CF, Wu TC (2020) Coronavirus vaccine development: from SARS and MERS to COVID-19. Journal of Biomedical Sciences. 27 (1): 1-23. doi: 10.1186/s12929-020-00695-2
2. Bok K, Sitar S, Graham BS, Mascola JR (2021) Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. Immunity. 54 (8): 1636-1651. doi: 10.1016/j.immuni.2021.07.017
3. Heinz FX, Stiasny K (2021) Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. npj Vaccines. 6 (1): 1-13. doi: 10.1038/s41541-021-00369-6
4. Hervé C, Laupèze B, Del Giudice G, Didierlaurent AM, Da Silva FT (2019) The how’s and what’s of vaccine reactogenicity. npj Vaccines. 4: 39. doi: 10.1038/s41541-019-0132-6
5. Almufty HB, Mohammed SA, Abdullah AM, Merza MA (2021) Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study. Diabetes and Metabolic Syndrome. 15 (5): 102-207. doi: 10.1016/j.dsx.2021.102207
6. Riad A, Sağıroğlu D, Üstün B, Pokorina A, Klugrova J, Attia S, Klugar M (2021) Prevalence and risk factors of coronavac side effects: An independent cross-sectional study among healthcare workers in Turkey. Journal of Clinical Medicine. 10 (12): 2629. 1-13. doi: 10.3390/jcm10122629
7. World Health Organization (2021) Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19. WHO reference number: WHO/2019-nCoV/vaccines/SAGE_recommendation/Sinovac-CoronaVac/background/2021.1.
8. Montgomery J, Ryan M, Engler R, Hoffman D, McClenathan B, Collins L, Loran D, Hrnicr D, Herring K, Platzer M, Adams N, Sanou A, Cooper LT(2021) Myocarditis following immunization with mrna covid-19 vaccines in members of the US military. JAMA Cardiology. 6 (10): 1202-1206. doi: 10.1001/jamacardio. 2021.2833
9. Fernandes A, Chaudhari S, Jamil N, Gopalakrishnan G (2021) COVID-19 Vaccine. Endocrine Practice. 27 (2): 170-172. doi: 10.1016/j.eprac.2021.01.013
10. Mallapaty BS, Callaway E, Kozlov M, Ledford H, Noorden R Van (2021) How Covid vaccines shaped 2021 - in eight the race to vaccinate. The Nature. 600: 580-583. doi: 10.1038/d41586-021-03686-x
11. Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC (2022) Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infectious Diseases. 3099 (22): 1-10. doi: 10.1016/s1473-3099(22)00320-6
12. National Center For Disease Control, Libya (2022) The epidemiological situation of corona disease. National Center For Disease Control-Libya. Published. Accessed July 13, 2022. https://ncdc.org.ly/Ar.
13. DeJonckheere M, Vaughn LM (2019) Semistructured interviewing in primary care research: a balance of relationship and rigour. Family Medicine and Community Health. 7 (2): 1-8. doi: 10.1136/fmch-2018-000057
14. Cohen J (1988) Statistical power analysis for the behavioral sciences. Second edition. Lawrence Erlbaum Associates, Publishers, USA. ISBN: 0-8058-0283-5.
15. Al Bahrani S, Albarrak A, Alghamdi OA, et al. (2021) Safety and reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia. International Journal of Infectious Disease. 110:359-362. doi: 10.1016/ j.ijid.2021.07.052
16. Riad A, Pokorná A, Attia S, Klugarová J, Koščík M, Klugar M (2021) Prevalence of covid-19 vaccine side effects among healthcare workers in the Czech Republic. Journal of Clinical Medicine. 10 (7): 1-18. doi: 10.3390/jcm10071428
17. Menni C, Klaser K, May A, Polidori L, Capdevila J (2021) Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infectious Diseases. 21 (7): 939-949. doi: 10.1016/S1473-3099(21)00224-3

Citation :

Al-Zawam et al. (2022) Prevalence of reactogenicity of COVID-19 vaccine among Libyan adults: a cross-sectional study. Mediterr J Pharm Pharm Sci. 2 (4): 48-53. [Article number: 89]. https://doi.org/10.5281/zenodo.7479756